December 10 - 12, 2024 | Boston, MA
www.covalent-drug-discovery.com

REGISTER BY NOVEMBER 15 TO SAVE UP TO $300

WELCOME
EXPERT SPEAKERS
AGENDA
PARTNER WITH US
REGISTER YOUR PLACE

2nd Annual

Covalent Drug Discovery & Development Summit

Eliminating the Boundaries of Druggability with Novel Covalent Drugs

Discover & Develop Selective, Clinically Validated & Novel Covalent Therapeutics to Expand the Targetable Proteome & Non-Cysteine Amino Acid Space in Oncology, Immunology & Beyond

Expert Speakers Include:

Doug Johnson
Senior Director
Biogen

Iván Cornella
Chief Scientific Officer
Covant Therapeutics

Andrea Zuhl
Vice President, Chemical Biology & Proteomics
HYKU Biosciences

Monica Schenone
Senior Director & Head of Chemical Biology & Proteomics
Pfizer

David Weinstein
Vice President & Head of Chemistry
Vividion Therapeutics

Rhamy Zeid
Vice President & Head of Biology
Nexo Therapeutics

Proud to Partner With:

药明康德 WuXi AppTec

momentum BIOTECHNOLOGIES

+1 617 455 4188 info@hansonwade.com
www.covalent-drug-discovery.com The UnDruggable Series

hansonwade

Welcome to the 2nd Covalent Drug Discovery & Development Summit

Covalent Drug Discovery & Development Summit

December 10-12, 2024 | Boston, MA

Continued advancements in proteomics, emergence of covalent biologics, and progression of drug pipelines into the clinic are poising the next wave of covalent drugs against hard-to-target proteins and amino acids across a plethora of disease indications.

The **2nd Covalent Drug Discovery & Development Summit** returns to enrich your pipeline strategies to **pursue a diverse range of protein targets,** spanning validated receptors to historically "undruggable" targets with first- and best-in class **covalent inhibitors, modulators, degraders and beyond**.

Uniting 100+ Heads, Directors and VPs of **Proteomics**, **Medicinal Chemistry**, **Chemical Biology**, **Discovery Biology** and **Pharmacology** as well as **KOLs of academia**, this year's industry- and translational-dedicated agenda is one step ahead in addressing your most prevalent pain points, such as:

- Leveraging lysine-based covalency across the disease spectrum to develop best- and first-in-class therapies against known and previously undruggable targets
- Minimizing off-target toxicity of your covalent drugs while developing high target specificity in oncology and chronic conditions, such as inflammation
- Accelerating your chemical biology enabled covalent drug discovery from hit to clinic against WRN, transcription factors, E3 ligases and beyond

Built with insights from **Covant Therapeutics**, **HYKU Biomedicines**, **Vividion Therapeutics** and more, join your peers to explore the depth and breadth of covalency from **discovery to translation and clinical development** - setting you up to overcome hit discovery, PKPD and efficacy bottlenecks to successfully develop potent covalent drugs for unmet clinical need.

Event in Numbers

100+ Attendees

16+ New Case Studies

8 Hours of Networking

2 Deep-Dive Workshops

5 KEY BENEFITS OF ATTENDING

Overcome challenges in balancing reactivity and sensitivity with advanced screening cascades to rationally develop covalent handles and streamline the triage of tractable compounds with insights from **Genentech**, **Scorpion Therapeutics** & **Covant Therapeutics**



Supercharge the discovery of highly selective covalent drugs by advancing chemoproteomic platforms and novel probes to assess pharmacology and mitigate their highly contested off-target safety risks with input from **Biogen**, **Nexo Therapeutics** & **Lundbeck**



Propel the development of novel warheads for covalent screening of histidine, tyrosine and lysine residues to expand the druggable proteome and target novel binding pockets with insights from **HYKU Biomedicines**, **Arminda Labs** & **Bayer**

Unlock novel disease indications stemming immunology, inflammatory and CNS conditions by progressing the identification and validation of covalent drugs for hard-to-drug targets beyond KRAS G12C, BTK and EGFR with drug discovery and clinical insights from **Novartis**, **Taiho Pharmaceutical** & **Covant Therapeutics**



Advance covalency beyond irreversible inhibition by tapping into the advancing paradigm of covalent PROTACs, monovalent degraders and highly selective biologics, charting the course for first-in-class drugs with insights from **Harvard**, **Pfizer** & **Amgen**

+1 617 455 4188 info@hansonwade.com
www.covalent-drug-discovery.com The UnDruggable Series
hansonwade

What's New For 2024?

New Companies Speaking on the Agenda

UC Riverside · Genentech · Harvard University · HYKU Biosciences · nexo therapeutics · Taiho Pharma · NF Funded by Novartis · Bayer · Lundbeck · Pfizer · R|S Oncology Beyond Expectations · vividion therapeutics

Join our Growing Community



New & Noteworthy Sessions Include

Specific Covalent Targeting of Histidine, Tyrosine & Lysine to Expand the Druggable Proteome

Andrea Zuhl, Vice President, Chemical Biology & Proteomics, **HYKU Biosciences**

Towards a Chemical Biology Platform for the Systematic Discovery & Evaluation of Novel Covalent Chemistry

Sebastian Essig, Director & Group Leader, Chemical Biology, **Bayer**

Innovating the Development of Covalent Molecular Glues Displaying Improved Efficacy through Specific & Durable Interactions

Stefan Andrew Harry, Postdoctoral Fellow, **Harvard University & MGH Cancer Center (Bar-Peled & Liau Lab)**

Examining Partner & Investor Perspectives to Fulfil the Future Opportunities of Covalent Drug Discovery & Development

Adam Cotton, Analyst, **Novartis Venture Fund**

Mark Springel, Senior Associate, **Vida Ventures**

Rhamy Zeid, Vice President & Head of Biology, **Nexo Therapeutics**

Showcase Your Scientific Poster

Contribute to the conversation and share your cutting-edge research with your fellow covalency community to communicate your discoveries to a vast audience of experts.

Register your place and submit an abstract for review to showcase your poster*

*Please visit the website for the Ts&Cs for presenting a poster

Your Expert Speakers

Xiang Yi
Senior Principal Scientist
Amgen

Sebastian Essig
Director & Group Leader, Chemical Biology
Bayer

Jin Wang
Professor & Director of Centre for NextGen Therapeutics
Baylor College of Medicine

Doug Johnson
Senior Director
Biogen

Iván Cornella
Chief Scientific Officer
Covant Therapeutics

Jamie Rice
Senior Director & Head of Discovery Biology
Covant Therapeutics

Brett Babin
Principal Scientist
Genentech

Stefan Andrew Harry
Postdoctoral Fellow
Harvard University & MGH Cancer Center (Bar-Peled & Liau Lab)

Andrea Zuhl
Vice President, Chemical Biology & Proteomics
HYKU Biosciences

Micah Niphakis
Director of Chemical Biology & Proteomics
Lundbeck La Jolla Research Center

William LaMarr
Senior Vice President of Research & Development
Momentum Biotechnologies

Rhamy Zeid
Vice President & Head of Biology
Nexo Therapeutics

Adam Cotton
Associate
Novartis Venture Fund

Lynn McGregor
Senior Principal Scientist
Novartis

Jaimeen Majmudar
Senior Principal Scientist
Pfizer

Monica Schenone
Senior Director & Head of Chemical Biology & Proteomics
Pfizer

George Naumov
Chief Operating Officer
RS Oncology

Brent Martin
Vice President & Head of Chemical Biology
Scorpion Therapeutics

Takeshi Sagara
Managing Director, Clinical Development Medical Affairs, Discovery & Preclinical Research
Taiho Pharmaceutical

Maurizio Pellecchia
Professor of Biomedical Sciences, Director Center for Molecular & Translational Medicine
University of California Riverside
President & Co-Founder
Armida Labs (Riverside)

Ken Hsu
Associate Professor
The University of Texas at Austin

Mark Springel
Senior Associate
Vida Ventures

David Weinstein
Vice President & Head of Chemistry
Vividion Therapeutics

Pre-Conference Workshop Day
Tuesday December 10, 2024

Workshop A
9.00 - 12.00

Interrogating & Optimizing Covalent Library Design to Improve the Generation of Viable Hits that Efficiently Engage the Target & Display Improved Safety Profiles

Comprehensive library design is crucial for identifying viable hits and warheads with the potential to advance into potent and selective covalent drugs. Creating effective covalent libraries, including optimizing molecular size and diversity, achieving target specificity, and balancing electrophile reactivity poses obstacles in ensuring libraries are both synthetically feasible and efficient in target engagement, while avoiding off-target interactions. This workshop will equip you with strategies to overcome these hurdles by leveraging state-of-the-art methodologies for respective screening platforms and insights from recent advancements in covalent drug discovery.

This workshop will discuss:

- What is the optimal library size for balancing build capacity and screening efficiency?
- How can you determine the appropriate molecular size and diversity for your library? How can we leverage different screening techniques to broaden this?
- How to inform which electrophiles should be incorporated, and how reactive should they be to minimize off-target toxicities
- How can you ensure the synthetic ease of library compounds?
- How to ensure your library is enabling effective engagement with your targets of interest

Workshop Leader

Sebastian Essig
Director & Group Leader, Chemical Biology
Bayer

Workshop B
1.00 - 4.00

Fast-Track Target Validation to De-Risk Covalent Drug Discovery Pipelines in Oncology & Beyond

From undrugged oncology targets to immunology and CNS indications with unmet patient need, the renaissance in covalent modalities continues to present huge promise in expanding the paradigm of druggable targets. However unlocking difficult-to-drug proteins and establishing pipelines in pursuit of first-in-class drugs remains no easy feat, with persistent challenges in distinguishing tractable targets, optimizing target engagement, and minimizing off-target effects. Tackling these bottlenecks head-first, this workshop will address the critical target identification, validation and chemical biology challenges allowing you to de-risk your future pipeline.

This workshop will address:

- How to de-risk and assess the tractability of covalency for different targets
- What are the key criteria for selecting covalent drug targets? And how does this differ between indications?
- How to leverage advanced screening technologies to enhance target identification
- How to effectively validate target engagement and through what methodologies
- What role does structural biology play in understanding target interactions?
- Debating the best practices for optimizing target specificity and selectivity

Workshop Leader

Jamie Rice
Senior Director & Head of Discovery Biology
Covant Therapeutics

Conference Day One
Wednesday December 11, 2024

8.00 **Check-In & Light Breakfast**

Iván Cornella
Chief Scientific Officer
Covant Therapeutics

8.50 **Chair's Opening Remarks**

Streamlining Hit Generation with High-Throughput & Unbiased Covalent Screens to Define Innovative Warheads for Hard-to-Drug Targets

Lynn McGregor
Senior Principal Scientist
Novartis

9.00 **Covalency Offers Unique Opportunities for Difficult Targets**

- Covalency provides opportunities for difficult drug targets
- Screening identifies a starting point for a TF target
- Proteomics is an essential tool for covalency focused efforts

Brett Babin
Principal Scientist
Genentech

9.30 **Mass Spectrometry Screening & Hit Optimization Strategies for Efficient Covalent Drug Discovery**

- Maximizing throughput for MS-based covalent screens
- Integrating data generated from MS screens to identify potent and selective hit compounds
- Triaging hits to identify the most tractable compounds

NEW DATA

10.00 **Panel Discussion: Debating Systematic & Scalable Screening Methods to Rationally Discover & Develop Covalent Handles with Optimized Reactivity & Selectivity**

- Debating the pros and cons of target-agnostic and target-focused screening to identify the best use cases
- What are the best methods for finding tractable hits?
- Discussing how to balance reactivity with sensitivity within screening cascades
- Streamlining hit to lead by sifting through hits and appropriately triaging

Panel Moderator:

Iván Cornella
Chief Scientific Officer
Covant Therapeutics

Maurizio Pellecchia
Professor of Biomedical Sciences, Director
Center for Molecular & Translational Medicine
University of California Riverside
President & Co-Founder
Armida Labs (Riverside)

Brett Babin
Principal Scientist
Genentech

David Weinstein
Vice President & Head of Chemistry
Vividion Therapeutics

Monica Schenone
Senior Director & Head of Chemical Biology & Proteomics
Pfizer

11.00 **Morning Break & Speed Networking**
Our speed networking session is the ideal opportunity to get face-to-face time with many of the brightest minds working to discover and develop covalent modalities. Introduce yourself to the attendees that you would like to have more in-depth conversations with, benchmark against industry leaders, and establish meaningful business relationships that you can pursue for the rest of the conference and beyond

Conference Day One
Wednesday December 11, 2024

Accelerating the Development of Unbiased & Scalable Platforms to Access & De-Risk Novel Chemistry Amenable for Covalency & Propel Discovery Pipelines

Brent Martin
Vice President & Head of Chemical Biology
Scorpion Therapeutics

12.00 **Practical Approaches to Accelerate Covalent Drug Discovery**

- Exploring early profiling and selection of actionable targets
- Assessing hits to predict target tractability
- Enabling biochemical and chemoproteomics assays to build programs

NEW DATA

Xiang Yi
Senior Principal Scientist
Amgen

12.30 **Mechanistic Study of Reversible & Irreversible Covalent Inhibitors**

- The emergence of reversible covalency addresses off-target safety concerns, countering challenges posed by irreversible covalent inhibitors. Yet, characterization of this novel mechanism is hindered by limited assays and tools
- Establishing enzyme kinetic assays, incorporating slow binding Ki Kinact measurement and jump dilution to enable the determination and differentiation of reversible from irreversible covalency mechanism

NEW DATA

1.00 **Session Reserved for WuXi AppTec**

1.30 **Lunch Break & Networking**

Spearheading the Specific Covalent Targeting of More Abundant Residues Beyond Cysteine to Access Novel Binding Pockets & Expand the Druggable Proteome

Andrea Zuhl
Vice President, Chemical Biology & Proteomics
HYKU Biosciences

2.30 **Specific Covalent Targeting of Histidine, Tyrosine & Lysine to Expand the Druggable Proteome**

- Development of novel warheads for covalent screening of histidine, tyrosine and lysine residues
- Enhancing the capture and mass spectrometry detection of sensitive peptide-ligand pairs
- Integration of structural information to prioritize novel binding pockets for further development of covalent or non-covalent compounds

BEYOND CYSTEINE NEW DATA

Maurizio Pellecchia
Professor of Biomedical Sciences, Director Center for Molecular & Translational Medicine
University of California Riverside
President & Co-Founder
Armida Labs (Riverside)

3.00 **Targeting of Histidine Residues to Increase the Pool of Potential Targets Amendable for Covalent Drug Discovery**

- Showcasing how to identify and map histidine residues across a wide range of proteins to determine their potential as covalent drug targets
- How to marry the right electrophiles with histidine moieties
- Ligand-first versus electrophile-first approaches to target Histidine residues

BEYOND CYSTEINE NEW DATA

3.30 **Afternoon Networking Break**

Conference Day One
Wednesday December 11, 2024

Advancing Chemoproteomic Platforms & Probes to Better Interrogate Novel Biology & Amplify the Druggable Proteome Outside Oncology

Sebastian Essig
Director & Group Leader
Chemical Biology,
Bayer

4.00 **Towards a Chemical Biology Platform for the Systematic Discovery & Evaluation of Novel Covalent Chemistry**

- Exploring insights into flexible library setup to synthesis novel covalent warhead libraries
- Showcasing MS and proteomics-based discovery and profiling assays for novel covalent warhead motifs
- Examining setups to screen and profile novel covalent libraries

NEW DATA

Lynn McGregor
Senior Principal Scientist
Novartis

4.30 **Roundtable Discussion: Fueling the Covalency Renaissance by Strategizing the Chemistry Toolbox to Target Residues Beyond Cysteine with Orthogonal Reactivity**

- Which amino acids are seen as the next frontier in covalent drug discovery?
- What is the mass spectrometry or alternative screening toolbox for other amino acids?
- How can we build drug-like warheads that hit other sidechains? Should we be screening these more promiscuous warheads?
- What are the different methods to validate non-cysteine covalency in simplified systems?

Rhamy Zeid
Co-founder & Vice President, Head of Biology
Nexo Therapeutics

5.00 **Covalent Fragment-Based Ligand Discovery to Drug Refractory Targets**

- How can covalent fragment-based ligand discovery be leveraged to tackle so-called undruggable targets?
- What are the advantages of a target-centric approach to covalent fragment-based ligand discovery?
- What approaches (biochemical and cell-based) can be deployed to progress covalent fragment starting points to mature lead molecules within a drug discovery campaign?

BEYOND CYSTEINE NEW DATA

Iván Cornella
Chief Scientific Officer
Covant Therapeutics

5.30 **Chairs Closing Remarks**

5.35 **End of Conference Day One**

> "There is tremendous value in sharing ideas in a collaborative and dynamic forum to learn from others' experiences and identify the most important questions we should be asking right now that will lead to better therapies for patients tommorrow"
>
> Senior Director & Head, **Covant Therapeutics**

Conference Day Two
Thursday December 12, 2024

8.00 **Check-In & Morning Coffee**

8.40 **Chair's Opening Remarks**

Debunking & Addressing Idiosyncratic Toxicity Amongst Current Covalency Programs to Improve Safety Profiles & Accelerate IND-Filing

Micah Niphakis
Director of Chemical Biology & Proteomics
Lundbeck La Jolla Research Center

9.00 **Profiling Approved Covalent Drugs to Guide Multiparameter Optimization of Covalent Drug Candidates**

- Evaluating intrinsic reactivity and *in vitro* metabolism for representative approved covalent drugs
- Chemoproteomic profiling to gain insights into covalent binding burden and proteome-wide selectivity
- Considerations for optimization of covalent drug candidates based on approved covalent drug profiles

NEW DATA

Doug Johnson
Senior Director
Biogen

9.30 **Chemoproteomic Profiling of Covalent Inhibitors in Multiple Cell Types to Assess Pharmacological Targets & Off-Target Safety Risks**

- Chemoproteomic profiling using clickable probes of covalent inhibitors in multiple cell types is a crucial technique for evaluating their proteome-wide selectivity to assess target engagement and off-targets
- Importance of selecting appropriate cell lines and organ systems for screening covalent inhibitors to comprehensively assess potential off-target toxicities
- While no single method can definitively determine a compound's propensity for causing DILI, broadening the scope of chemoproteomic profiling to encompass liver systems in the evaluation of covalent inhibitors could pinpoint off-targets to avoid, thereby helping to mitigate the risk of DILI

NEW DATA

William LaMarr
Senior Vice President of Research & Development
Momentum Biotechnologies

10.00 **Accelerating "Speed to Answer" for the Discovery of Covalent Therapeutics**

- Integrated workflows that utilize standardized plate maps, automated robotics and high-throughput MS instrumentation to maximize the productivity of the already powerful mass spec based technology
- High-throughput MS platform enabling covalent library screening at < 15 seconds per sample enabling collections of >10,000 compounds to be screened in ~ 2 days
- Standardized SOPs using commercially available hardware/software packages producing dozens of potency (Kinact/Ki) and selectivity (peptide mapping) measurements a day
- Activity based protein profiling (ABPP) workflows elucidating both on-target and off-target engagement in a cellular setting

Fueling the Covalency Renaissance to Increase Investment & Partnership to Expand the Paradigm of Treatable Diseases

10.15 **Panel Discussion: Examining Partner & Investor Perspectives to Fulfil the Future Opportunities of Covalent Drug Discovery & Development**

- What is investible when considering the covalency programs/platforms?
- What do investors look for when investing in covalent pipelines? Is a particular target or indication of interest?
- How to secure interest from collaboration partners and discussing how assets are considered versus platforms

Adam Cotton
Analyst
Novartis Venture Fund

Mark Springel
Senior Associate
Vida Ventures

Rhamy Zeid
Vice President & Head of Biology
Nexo Therapeutics

11.00 **Morning Break & Scientific Poster Session**
As the research, discovery, and development into covalent therapies continues to progress from strength to strength, it is more important than ever to collaborate and learn with your peers, as we continue to advance these therapies to patients in need. Join your colleagues to share your latest data and have the first look into what your peers are working on!

Conference Day Two
Thursday December 12, 2024

Igniting Covalent Modalities Beyond Inhibition to Harness Diverse Mechanisms of Action for First-in-Class Covalent Drugs

Stefan Andrew Harry
Postdoctoral Fellow
Harvard University & MGH Cancer Center (Bar-Peled & Liau Lab)

12.00 **Innovating the Development of Covalent Molecular Glues Displaying Improved Efficacy through Specific & Durable Interactions**

- Defining the ligandable space of the Cysteinome
- Utilizing dual-covalent "superglues" to expand the targetable proteome
- What are the consequences of supergluing proteins?

NEW DATA

Jin Wang
Professor & Director of Centre for NextGen Therapeutics
Baylor College of Medicine

12.30 **Lessons Learned from Developing Covalent Inhibitors & Covalent PROTACs**

- Applying chemoproteomics to characterize covalent inhibitor reactivity in the proteome
- Developing a covalent BTK PROTAC with single digit nM DC50
- Elucidating the ternary complex structure of the covalent BTK PROTAC

NEW DATA

Jaimeen Majmudar
Senior Principal Scientist
Pfizer

1.00 **A Covalent, Allele-Specific Monovalent Degrader for the Treatment of NASH**

- Phenotypic screen points to a degrader; MoA determination and target deconvolution
- Chembio and covalency leveraged to identify a clinical candidate
- Carrying and de-risking covalency from discovery to clinical development of asset in FIH

NEW DATA

1.30 **Lunch Break & Networking**

Examining Pre-Clinical & Translational Cases to Inform & De-Risk the Strategy for Progressing Emerging Covalent Compounds Towards a Quicker Approval

Ken Hsu
Associate Professor
The University of Texas at Austin

2.30 **Covalent Strategies for Targeting the Kinome**

- Describing the synthesis of sulfonyl-triazoles as a new phenol-reactive group for covalent modification of tyrosine and lysine residues on proteins through sulfur-triazole exchange (SuTEx) chemistry
- The reactivity of SuTEx chemistry is highly tunable, which can facilitate optimization of potent and selective binders to orthosteric and allosteric sites on kinases
- Showcasing efforts to use lead SuTEx inhibitors for modulating kinase function in cells

NEW DATA

Takeshi Sagara
Managing Director, Clinical Development & Medical Affairs, Discovery & Preclinical Research
Taiho Pharmaceutical

3.00 **Discovery of the First Approved Covalent FGFR Inhibitor, Futibatinib, by Cysteinomix Drug Discovery Approach**

- What is the optimal profile of a covalent drug targeting FGFRs, considering target engagement, PKPD, safety and tolerability?
- How to design covalent binding drugs to capture Cys on highly flexible loop structures
- What is the desirable platform to continuously deliver covalent binding drug candidates into clinical space?

George Naumov
Chief Operating Officer
RS Oncology

3.30 **Clinical Development of RSO-021, a Novel Covalent Inhibitor Targeting Mitochondrial PRX3**

- What is the optimal profile of a covalent drug targeting PRX3, considering target engagement, PKPD, safety and tolerability?
- How to design and implement clinical trials to validate the safety, efficacy, and specificity of covalent modification strategies, and with what biomarkers?
- How to predict and mitigate the long-term effects and potential for cumulative toxicity of covalent drugs in patients

4.00 **Chairs Closing Remarks**

4.05 **End of 2nd Covalent Drug Discovery & Development Summit**

Our 2024 Partners

Expertise Partner

WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the pharmaceutical and healthcare industry around the world to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec's integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, and cell and gene therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions.

www.wuxiapptec.com

Innovation Partner

Momentum Biotechnologies is a specialized CRO focused on providing mass spectrometry-based native detection technologies for lead discovery to biopharmaceutical clients. Formerly known as Pure Honey Technologies, Momentum Biotechnologies proudly maintains its unwavering commitment to delivering the same high-quality MS-based services, supportive staff, adaptable study options, superior data quality, and rapid delivery of experimental results. We help clients identify leads for novel mechanisms of action such as protein degradation/molecular glues, protein-protein interaction disruption (ASMS), and irreversible binding (Covalent Screening).

www.momentum.bio

> "The Covalent Drug Discovery Summit was a great way to hear where colleagues across the industry agree and to hear examples where people are taking slightly different strategies to reach in some cases, similarly successful outcomes"
>
> Past Attendee, **Novartis**

GET INVOLVED

Marinela Tice
Partnerships Director
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com

Partner With Us

Covalent Drug Discovery & Development Summit

December 10-12, 2024 | Boston, MA

Your Comprehensive, Industry-Dedicated Global Platform to Foster New & Existing Relationships within the Surging Covalent Community

Capitalizing on the breakthroughs of the covalent KRAS G12C inhibitors, the momentum to deploy covalency as a primary drug discovery effort continues to grow, drawing in new and distinguished biopharma in the race to develop first-in-class covalent drugs for previously hard-to-drug targets. The **2nd Covalent Drug Discovery & Development Summit** serves as a central hub for leading experts committed to discovering, validating and clinically progressing safe and efficacious covalent inhibitors, PROTACs, and monovalent drugs to improve patient outcomes.

With this shared aspiration in mind, partner with us to showcase how your business can address the limitations of key drug developers and leading experts by offering solutions and services in:

- Assay Development
- Covalent Library and Screening Capabilities
- Computational Platforms
- Chemoproteomics
- Biophysics Characterization
- Preclinical and Clinical Services

Benefit From Market Intelligence

With the covalency renaissance heating up, hear how and where biopharma are searching for services and solutions to facilitate their efforts to develop, validate and clinically progress novel covalent inhibitors, heterobifunctionals, monovalents and biologics and **match your premium services** accordingly

Showcase your World-Class Solutions

Benefit from pre- and post-conference exposure to our booming covalent community and increase market share through unique branding formats. Differentiate your discovery and pre-clinical services from other solution providers to **stand out amongst the competition**

Forge New Commercial Collaborations

With an all-encompassing room full of drug developers and decision makers dedicated to broadening the druggable proteome through covalency, **meet prospective clients** during speed networking breaks and informal networking receptions

SENIORITY OF ATTENDEES*



- Chief, President & VP – 31%
- Director & Head – 37%
- Professor – 5%
- Manager – 3%
- Scientist – 20%
- Other – 4%

TYPES OF COMPANIES ATTENDING*



- Drug Developers
- Academia & Research Institutes
- Equipment & Service Providers

*Statistics from the inaugural Covalent Drug Discovery Summit

GET INVOLVED

Marinela Tice
Partnerships Director
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com

Ready to Register?

3 Easy Ways to Book

www.covalent-drug-discovery.com/take-part/register/

Tel: +1 617 455 4188

Email: info@hansonwade.com

DISCOVER and leverage first-hand technical and strategic insights from leading biopharma organizations striving to expand the druggable proteome through pioneering **cysteine, lysine, tyrosine** and **histidine covalency**

BUILD your understanding into the current challenges, strategies, and solutions to truly capitalize on the covalency renaissance with the development of **next generation inhibitors** and **emerging modalities**

ENGAGE with your growing community and 100+ peers from leading biopharma and academia with networking opportunities to **build complementary collaborations** and **partnerships**

Drug Developer* Pricing	Early Bird Rate Expires Friday, November 15	On the Door Rate
Conference + 2 Workshops	$3,897 (save $300)	$4,197
Conference + 1 Workshop	$3,338 (save $300)	$3,638
Conference Only	$2,779 (save $220)	$2,999
Academic & Not-for-Profit Pricing**	Early Bird Rate Expires Friday, November 15	On the Door Rate
Conference + 2 Workshops	$3,297 (save $300)	$3,597
Conference + 1 Workshop	$2,838 (save $300)	$3,138
Conference Only	$2,379 (save $220)	$2,599
Service & Solution Provider Pricing	Early Bird Rate Expires Friday, November 15	On the Door Rate
Conference + 2 Workshops	$4,797 (save $300)	$5,097
Conference + 1 Workshop	$4,172 (save $260)	$4,432
Conference Only	$3,479 (save $220)	$3,699

*To qualify for the drug developer rate your company must have a public drug pipeline and not offer pay-for services.. Please visit the website for full pricing options or email info@hansonwade.com

**To qualify for the academic rate you must be a full time academic. Please visit the website for full pricing options or email info@hansonwade.com

Do you work for a Not-for-Profit organization? Email us at info@hansonwade.com to inquire about attending

Team Discounts***

- **10% discount – 2 Attendees**
- **15% discount – 3 Attendees**
- **20% discount – 4+ Attendees**

***Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.

Contact: info@hansonwade.com

Venue

Hilton Boston Logan Airport

One Hotel Dr, Boston, MA 02128, United States

For further information or assistance, please visit:

www.hilton.com/en/hotels/boslhhh-hilton-boston-logan-airport/

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Every reasonable effort will be made to adhere to the event programme as advertised. However, it may be necessary to alter the advertised content, speakers, date, timing, format and/or location of the event. We reserve the right to amend or cancel any event at any time. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Hanson Wade Ltd, Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH, United Kingdom